Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
Cytokinetics (Nasdaq: CYTK) announced a poster presentation for the FORTITUDE-ALS Phase 2 clinical trial of reldesemtiv, focusing on ALS survival predictions. This session will occur during the Virtual 33rd International Symposium on ALS/MND from December 6-9, 2022. Dr. Tyrell Simkins will present the ENCALS Predictive Survival Model on December 8, 2022, from 5:00-6:30 PM GMT. Cytokinetics specializes in muscle performance therapies and is advancing several clinical candidates, notably omecamtiv mecarbil and aficamten, targeting significant heart conditions and diseases.
Cytokinetics announced new data from the GALACTIC-HF trial, presented at the American Heart Association Scientific Sessions 2022. The trial revealed that treatment with omecamtiv mecarbil significantly reduced heart failure hospitalizations and associated costs, averaging a 26.9% cost reduction over three years. Analysis showed omecamtiv mecarbil reduced cardiovascular death and heart failure events in North American patients with EF ≤30%. The treatment's efficacy showed no significant gender differences despite worse quality of life for women at baseline.
Cytokinetics (CYTK) reported a net loss of $142.3 million ($1.52/share) in Q3 2022, up from $76.1 million ($0.95/share) in Q3 2021. Despite the loss, cash and equivalents stood at $896.2 million. Revenue for Q3 was $2.5 million, with a significant nine-month increase to $92.6 million, primarily due to $87 million from mavacamten royalties. The company is preparing for the potential U.S. launch of omecamtiv mecarbil and advancing various clinical trials, including aficamten and COURAGE-ALS, with results expected in 1H 2023.
Cytokinetics, Inc. (Nasdaq: CYTK) announced the grant of stock options for 202,500 shares to 20 new employees as an inducement to their employment, effective October 31, 2022. The options have an exercise price of $43.66 per share and will vest over four years. A quarter of the options will vest after one year, with the remainder vesting monthly over the following 36 months. This grant complies with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent critical to the company's growth in developing muscle performance treatments.
Cytokinetics announces three poster presentations at the American Heart Association Scientific Sessions 2022, from November 5 to 7, 2022, in Chicago, IL. Presentations will cover: 1) Heart failure patient profiles from the Get With The Guidelines®-Heart Failure Registry, 2) Healthcare resource use and cost analysis for North American patients likely to benefit from omecamtiv mecarbil, and 3) Analysis of sex differences in the GALACTIC-HF trial. Key presenters include experts from Duke University Medical Center and Yale School of Medicine.
Cytokinetics (NASDAQ: CYTK) will announce its third quarter earnings on November 3, 2022, at 4:00 PM ET, followed by a conference call at 4:30 PM ET to discuss operational and financial results. The call will be available via webcast on Cytokinetics' website. The company specializes in developing muscle activators and inhibitors for diseases affecting muscle performance, with ongoing clinical trials for its drug candidates ome-camtiv mecarbil, aficamten, and reldesemtiv. For further information, visit cytokinetics.com.
Cytokinetics announced the continuation of its Phase 3 clinical trial, COURAGE-ALS, after a Data Monitoring Committee (DMC) recommended proceeding following a first interim analysis. This trial evaluates the potential of reldesemtiv, a treatment for amyotrophic lateral sclerosis (ALS). Approximately 555 patients are expected to enroll, with the trial focusing on the efficacy of reldesemtiv over 24 weeks. A second interim analysis is expected in 2023 to assess potential futility and possibly increase patient enrollment.
Cytokinetics, Inc. (Nasdaq: CYTK) announced the granting of stock options for 99,000 shares to 10 new employees as of September 30, 2022. The options, priced at $48.45 per share, align with the closing stock price on that date and will vest over four years. This action adheres to Nasdaq rules as a material employment inducement. The company specializes in developing innovative muscle activators and inhibitors, with ongoing clinical trials for products addressing heart failure and hypertrophic cardiomyopathies.
Cytokinetics reported significant improvements in heart failure symptoms and quality of life associated with the treatment of aficamten during the REDWOOD-HCM OLE trial, presented at the HFSA Annual Meeting. Patients demonstrated substantial enhancements in self-reported health status per the Kansas City Cardiomyopathy Questionnaire, with KCCQ Overall Summary Score improvements of 16.5 at Week 12 and 17.6 at Week 24. Additionally, patients with worsening heart failure and LVEF ≤30% showed a notably high risk of hospitalization, emphasizing the unmet medical need in this demographic.
Cytokinetics has released promising data on the investigational drug aficamten during the REDWOOD-HCM OLE trial, showing its potential to facilitate the reduction or withdrawal of standard care therapies in patients with obstructive hypertrophic cardiomyopathy (HCM). Of 35 patients who completed treatment, 85% successfully reduced their medication doses, with some completely discontinuing standard therapies while maintaining clinical benefits. Cytokinetics plans to further investigate aficamten as a potential monotherapy in a forthcoming Phase 3 trial.